Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.04%
#2 Ocean Protocol Ocean Protocol +22.42%
#3 Audiera Audiera +15.20%
#4 Geodnet Geodnet +14.73%
#5 Arowana Arowana +7.85%
#6 DexNet DexNet +7.78%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +7.71%
#8 Ontology Gas Ontology Gas +6.77%
#9 Rollbit Coin Rollbit Coin +6.27%
#10 Cysic Cysic +6.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
MapLight Therapeutics, Inc. MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT
Rang in Aktien #32258
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm... MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Aktienkurs
$13.43
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$10.60M
Veränderung (1 Tag)
-4.26%
Veränderung (1 Jahr)
-
Land
US
Handel MapLight Therapeutics, Inc. (MPLT)

Kategorie

Healthcare
Operative Marge für MapLight Therapeutics, Inc. (MPLT)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von MapLight Therapeutics, Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von MapLight Therapeutics, Inc. von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.